United States

Palatin Technologies Inc (PTN.A)

PTN.A on American Stock Exchange

21 Jul 2017
Change (% chg)

$0.01 (+1.79%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Palatin Technologies reports Q3 loss per share $0.02
Tuesday, 16 May 2017 07:30am EDT 

May 16 (Reuters) - Palatin Technologies Inc -:Palatin Technologies Inc reports third quarter fiscal year 2017 results; teleconference and webcast to be held on May 16, 2017.Q3 loss per share $0.02.Palatin Technologies Inc says for quarter ended March 31, 2017, recognized $10.8 million in contract revenue related to license agreement with amag.Palatin Technologies - proceeds from license agreement with amag, capital resources will be adequate to fund planned operations through calendar year 2018.  Full Article

Amag Pharmaceuticals enters into an agreement to develop and commercialize Rekynda
Monday, 9 Jan 2017 08:00am EST 

Amag Pharmaceuticals Inc : Entered into an agreement for exclusive North American rights to develop and commercialize Rekynda . Anticipated filing date in U.S. for NDA for Rekynda is in early 2018, with an anticipated approval and launch by early 2019 . Under terms of license agreement, Amag will pay to Palatin $60 million of total upfront consideration .To reimburse palatin for up to $25 million of ongoing development expenses incurred by Palatin related to development of Rekynda in 2017.  Full Article

Palatin Technologies reports Q4 loss $0.09/shr
Tuesday, 20 Sep 2016 07:30am EDT 

Palatin Technologies Inc : Palatin Technologies, Inc. reports fourth quarter and fiscal year 2016 results . Q4 loss per share $0.09 .There were no revenues recorded in quarter or year ended June 30, 2016 or in quarter ended June 30, 2015.  Full Article

Palatin Technologies entered commercial supply agreement with unit of Catalent Pharma solutions
Thursday, 23 Jun 2016 10:22am EDT 

Palatin Technologies: On june 20, 2016 co entered commercial supply agreement with unit of catalent pharma solutions with an effective date of june 10 . Sec filing . Palatin intends to engage third parties to provide catalent with a supply of bremelanotide and disposable auto-injector device . All patients are projected to complete phase 3 clinical trials of bremelanotide for hypoactive sexual desire disorder, by q3 2016 . Palatin Technologies Inc Says Catalent Will Have Right To Supply At Least 80% Of Palatin's Needs For Product During Term Of Agreement . Initial term of agreement will continue for period of 5 years after date that is 60 days from date on which fda gives market regulatory approval of product Source - http://1.usa.gov/28Sj3cH (Bengaluru Newsroom; +1 646 223 8780).  Full Article

Palatin Technologies Q3 loss per share $0.08
Tuesday, 17 May 2016 07:35am EDT 

Palatin Technologies Inc : Believes that existing capital resources will be adequate to fund planned operations through quarter ending september 30, 2016 . Palatin technologies, inc. Reports third quarter fiscal year 2016 results; teleconference and webcast to be held on may 17, 2016 .Q3 loss per share $0.08.  Full Article

Palatin Technologies and Richter Terminate license agreement for Bremelanotide for Female Sexual Dysfunction
Monday, 21 Sep 2015 07:00am EDT 

Palatin Technologies Inc:Announces that the Company and Gedeon Richter (Richter) mutually and amicably agreed to terminate the license and collaboration agreement for bremelanotide for the treatment of female sexual dysfunction (FSD).  Full Article